The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Tiotropium Respimat Inhaler and the Risk of Death in COPD
Abstract
BACKGROUND: Tiotropium delivered at a dose of 5 μg with the Respimat inhaler showed efficacy similar to that of 18 μg of tiotropium delivered with the HandiHaler inhalation device in placebo-controlled trials involving patients with chronic obstructive pulmonary disease (COPD). Although tiotropium HandiHaler was associated with reduced mortality, as compared with placebo, more deaths were reported with tiotropium Respimat than with placebo. METHODS: In this randomized, double-blind, parallel-group trial involving 17,135 patients with COPD, we evaluated the safety and efficacy of tiotropium Respimat at a once-daily dose of 2.5 μg or 5 μg, as compared with tiotropium HandiHaler at a once-daily dose of 18 μg. Primary end points were the risk of death (noninferiority study, Respimat at a dose of 5 μg or 2.5 μg vs. HandiHaler) and the risk of the first COPD exacerbation (superiority study, Respimat at a dose of 5 μg vs. HandiHaler). We also assessed cardiovascular safety, including safety in patients with stable cardiac disease. RESULTS: During a mean follow-up of 2.3 years, Respimat was noninferior to HandiHaler with respect to the risk of death (Respimat at a dose of 5 μg vs. HandiHaler: hazard ratio, 0.96; 95% confidence interval [CI], 0.84 to 1.09; Respimat at a dose of 2.5 μg vs. HandiHaler: hazard ratio, 1.00; 95% CI, 0.87 to 1.14) and not superior to HandiHaler with respect to the risk of the first exacerbation (Respimat at a dose of 5 μg vs. HandiHaler: hazard ratio, 0.98; 95% CI, 0.93 to 1.03). Causes of death and incidences of major cardiovascular adverse events were similar in the three groups. CONCLUSIONS: Tiotropium Respimat at a dose of 5 μg or 2.5 μg had a safety profile and exacerbation efficacy similar to those of tiotropium HandiHaler at a dose of 18 μg in patients with COPD. (Funded by Boehringer Ingelheim; TIOSPIR ClinicalTrials.gov number, NCT01126437.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease
Calverley, P. M. A., Anderson, J. A., Celli, B., Ferguson, G. T., Jenkins, C., Jones, P. W., Yates, J. C., & Vestbo, J. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063070 · Cited by 3,248
Self-citationA 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease
Tashkin, D. P., Celli, B., Senn, S., Burkhart, D., Kesten, S., Menjoge, S., & Decramer, M. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805800 · Cited by 1,604
Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPD
Vogelmeier, C., Hederer, B., Glaab, T., Schmidt, H., Rutten-van Mölken, M. P. M. H., Beeh, K. M., Rabe, K. F., & Fabbri, L. M. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008378 · Cited by 684
Celli, B., Decramer, M., Kesten, S., Liu, D., Mehra, S., & Tashkin, D. P. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200906-0876oc · Cited by 281
Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis
Barr, R. G. (2006) · Thorax · doi:10.1136/thx.2006.063271 · Cited by 236
Singh, S., Loke, Y. K., Enright, P. L., & Furberg, C. D. (2011) · BMJ · doi:10.1136/bmj.d3215 · Cited by 227
Tiotropium versus placebo for chronic obstructive pulmonary disease
Karner, C., Chong, J., & Poole, P. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009285.pub3 · Cited by 210
Cardiovascular Safety of Tiotropium in Patients With COPD
Celli, B., Decramer, M., Leimer, I., Vogel, U., Kesten, S., & Tashkin, D. P. (2010) · Chest · doi:10.1378/chest.09-0011 · Cited by 184
Dong, Y., Lin, H.-H., Shau, W., Wu, Y., Chang, C., & Lai, M. (2012) · Thorax · doi:10.1136/thoraxjnl-2012-201926 · Cited by 140
The Safety of Tiotropium — The FDA's Conclusions
Michele, T. M., Pinheiro, S. P., & Iyasu, S. (2010) · New England Journal of Medicine · doi:10.1056/nejmp1008502 · Cited by 121
Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications
Singh, S., Loke, Y. K., Enright, P., & Furberg, C. D. (2012) · Thorax · doi:10.1136/thoraxjnl-2011-201275 · Cited by 121
Bias due to withdrawal in long‐term randomised trials in COPD: Evidence from the TORCH study
Vestbo, J., Anderson, J. A., Calverley, P. M. A., Celli, B. R., Ferguson, G. T., Jenkins, C. R., Yates, J., & Jones, P. (2010) · The Clinical Respiratory Journal · doi:10.1111/j.1752-699x.2010.00198.x · Cited by 86
Self-citationRodrigo, G. J., Castro-Rodríguez, J. A., Nannini, L. J., Plaza, V., & Schiavi, E. (2009) · Respiratory Medicine · doi:10.1016/j.rmed.2009.05.020 · Cited by 80
Treadmill Endurance During 2-Year Treatment With Tiotropium in Patients With COPD
Cooper, C. B., Celli, B. R., Jardim, J. R., Wise, R. A., Legg, D., Guo, J., & Kesten, S. (2013) · CHEST Journal · doi:10.1378/chest.12-2613 · Cited by 46
Self-citation“Lies, Damned Lies …” and Observational Studies in Comparative Effectiveness Research
Albert, R. K. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201212-2187oe · Cited by 42
Salpeter, S. R. (2009) · Drugs · doi:10.2165/11318580-000000000-00000 · Cited by 25
Cited by
Vogelmeier, C. F., Criner, G. J., Martinez, F. J., Anzueto, A., Barnes, P. J., Bourbeau, J., Celli, B. R., Chen, R., Decramer, M., Fabbri, L. M., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201701-0218pp · Cited by 3,187
Self-citationVogelmeier, C. F., Criner, G. J., Martinez, F. J., Anzueto, A., Barnes, P. J., Bourbeau, J., Celli, B. R., Chen, R., Decramer, M., Fabbri, L. M., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00214-2017 · Cited by 881
Self-citationChronic obstructive pulmonary disease
Barnes, P. J., Burney, P. G. J., Silverman, E. K., Celli, B. R., Vestbo, J., Wedzicha, J. A., & Wouters, E. F. M. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.76 · Cited by 734
Vogelmeier, C. F., Criner, G. J., Martinez, F. J., Anzueto, A., Barnes, P. J., Bourbeau, J., Celli, B. R., Chen, R., Decramer, M., Fabbri, L. M., et al. (2017) · Respirology · doi:10.1111/resp.13012 · Cited by 681
Self-citationTiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)
Buhl, R., Maltais, F., Abrahams, R., Bjermer, L., Derom, E., Ferguson, G., Fležar, M., Hébert, J., McGarvey, L., Pizzichini, E., et al. (2015) · European Respiratory Journal · doi:10.1183/09031936.00136014 · Cited by 315
Metadata
- Authors
- Wise, R. A., Anzueto, A., Cotton, D., Dahl, R., Devins, T., Disse, B., Dusser, D., Joseph, E., Kattenbeck, S., Koenen-Bergmann, M., Pledger, G., & Calverley, P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-10-17
- Volume
- 369
- Issue
- 16
- Pages
- 1491-1501
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2153441442
- Cited by
- 333
- References
- 16
- FWCI
- 44.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.